Emma McMurtry

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

Michael Friedländer, Ursula A. Matulonis, Charlie Gourley et al. · British Journal of Cancer · 2018 · 177 citations · Full text

Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) <i>BRCA</i> mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.

Jacob Korach, Simon Turner, Tsveta Milenkova et al. · Journal of Clinical Oncology · 2018 · 17 citations

Mixed-phenotype Acute Leukemia, Cancer Management, Pathology +22

Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer

S.N. Westin, Jennifer K. Litton, Rhys Williams et al. · Annals of Oncology · 2017 · 16 citations · Full text

Parp Inhibitor, Breast Oncology, Akt Inhibitor +9

PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.

Helena Earl, Anne-Laure Vallier, Wendi Qian et al. · Journal of Clinical Oncology · 2017 · 12 citations

Breast Oncology, Oncology, Breast Cancer Patients +14

Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

Ursula A. Matulonis, Michael Friedländer, Andreas du Bois et al. · Journal of Clinical Oncology · 2015 · 11 citations

Olaparib Trials, Cancer Management, Gynecology +20